EMAIL THIS PAGE TO A FRIEND

PloS one

Losartan Treatment Protects Retinal Ganglion Cells and Alters Scleral Remodeling in Experimental Glaucoma.


PMID 26505191

Abstract

To determine if oral losartan treatment decreases the retinal ganglion cell (RGC) death caused by experimental intraocular pressure (IOP) elevation in mice. We produced IOP increase in CD1 mice and performed unilateral optic nerve crush. Mice received oral losartan, spironolactone, enalapril, or no drug to test effects of inhibiting angiotensin receptors. IOP was monitored by Tonolab, and blood pressure was monitored by tail cuff device. RGC loss was measured in masked axon counts and RGC bodies by β-tubulin labeling. Scleral changes that could modulate RGC injury were measured including axial length, scleral thickness, and retinal layer thicknesses, pressure-strain behavior in inflation testing, and study of angiotensin receptors and pathways by reverse transcription polymerase chain reaction, Western blot, and immunohistochemistry. Losartan treatment prevented significant RGC loss (median loss = 2.5%, p = 0.13), while median loss with water, spironolactone, and enalapril treatments were 26%, 28% and 43%; p < 0.0001). The lower RGC loss with losartan was significantly less than the loss with spironolactone or enalapril (regression model p = 0.001; drug treatment group term p = 0.01). Both losartan and enalapril significantly lowered blood pressure (p< 0.001), but losartan was protective, while enalapril led to worse than water-treated RGC loss. RGC loss after crush injury was unaffected by losartan treatment (difference from control p = 0.9). Survival of RGC in cell culture was not prolonged by sartan treatment. Axonal transport blockade after 3 day IOP elevations was less in losartan-treated than in control glaucoma eyes (p = 0.007). Losartan inhibited effects of glaucoma, including reduction in extracellular signal-related kinase activity and modification of glaucoma-related changes in scleral thickness and creep under controlled IOP. The neuroprotective effect of losartan in mouse glaucoma is associated with adaptive changes in the sclera expressed at the optic nerve head.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

B4429
BIS-TRIS, BioPerformance Certified, cell culture tested, suitable for insect cell culture, ≥98.0%
C8H19NO5
B9754
BIS-TRIS, ≥98.0% (titration)
C8H19NO5
RES1161B-A7
BIS-TRIS, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production., suitable for cell culture
C8H19NO5
PHG0004
BIS-TRIS, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production, suitable for cell culture
C8H19NO5
B7535
BIS-TRIS, BioXtra, ≥98.0% (titration)
C8H19NO5
14879
BIS-TRIS, BioUltra, ≥99.0% (NT)
C8H19NO5
CDS020548
Enalapril, AldrichCPR
C20H28N2O5
S7903
Sucrose, BioXtra, ≥99.5% (GC)
C12H22O11
84097
Sucrose, BioUltra, for molecular biology, ≥99.5% (HPLC)
C12H22O11
S9378
Sucrose, ≥99.5% (GC)
C12H22O11
S0389
Sucrose, for molecular biology, ≥99.5% (GC)
C12H22O11
S1888
Sucrose, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥99.5% (GC)
C12H22O11
S8501
Sucrose, ≥99.5%
C12H22O11
S5016
Sucrose, ACS reagent
C12H22O11
16104
Sucrose, puriss., meets analytical specification of Ph. Eur., BP, NF
C12H22O11
S5390
Sucrose, Grade I, plant cell culture tested
C12H22O11
S5391
Sucrose, Grade II, plant cell culture tested
C12H22O11
S3929
Sucrose, meets USP testing specifications
C12H22O11
47289
Sucrose, analytical standard
C12H22O11